[go: up one dir, main page]

AR035857A1 - Fenilindoles; sus composiciones farmaceuticas y sus usos - Google Patents

Fenilindoles; sus composiciones farmaceuticas y sus usos

Info

Publication number
AR035857A1
AR035857A1 ARP020101341A ARP020101341A AR035857A1 AR 035857 A1 AR035857 A1 AR 035857A1 AR P020101341 A ARP020101341 A AR P020101341A AR P020101341 A ARP020101341 A AR P020101341A AR 035857 A1 AR035857 A1 AR 035857A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
unsubstituted
nhr2
nr2r3
Prior art date
Application number
ARP020101341A
Other languages
English (en)
Original Assignee
Novirio Pharmaceuticals Ltd
Univ Degli Studi Cagliari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novirio Pharmaceuticals Ltd, Univ Degli Studi Cagliari filed Critical Novirio Pharmaceuticals Ltd
Publication of AR035857A1 publication Critical patent/AR035857A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos derivados de fenilindol de fórmula (1) o una sal o profármaco aceptable para uso farmacéutico del mismo, en donde: (a) R1 es hidrógeno, acilo, -C(=O)H, -C(=W)H, -C(=O)R2, -C(=W)R2, -C(=O)OH, -C(=W)OH, -C(=O)OR2, -C(=W)OR2, -C(=O)SH, -C(=W)SH, -C(=O)SR2, -C(=W)SR2, -C(=O)NH2, -C(=W)NH2, -C(=O)NHR2, -C(=W)NHR2, -C(=O)NR2R3, -C(=W)NR2R3, -C(=W)NH-(CH2)p-(aminoácido) ó -(CH2)p-aminoácido; (b) R4', R5', R6', R7', R2", R3", R4", R5" y R6" son cada uno independientemente H, halo (F, Cl, Br ó I), -NO2, -CN, -OH, -OR2, -SH, -SR2, -NH2, -NHR2, -NR2R3, -NHSO2-alquilo C1-3, -NR2SO2-alquilo C1-3, -NHCO-alquilo C1-3, -NR2CO-alquilo C1-3, alquilo lineal o ramificado opcionalmente sustituido o insustituido, alquenilo o alquinilo (tal como un lineal o ramificado opcionalmente sustituido o insustituido alquilo C1-6, alquenilo C2-6 o alquinilo C2-6 y en particular CH3, CF3, bromuro de vinilo, -CR2R2-S(O)n-R3, -CR2R2NH2, -CR2R2NHR2, -CR2R2NR2R3 y -CR2R2-C(=O)R2), alcacilo, acilo opcionalmente sustituido o insustituido, -C(=O)H, -C(=W)H, -C(=O)R2, -C(=W)R2, -C(=O)OH, -C(=W)OH, -C(=O)OR2, -C(=W)OR2, -C(=O)SH, -C(=W)SH, -C(=O)SR2, -C(=W)SR2, -C(=O)NH2, -C(=W)NH2, -C(=O)NHR2, -C(=W)NHR2, -C(=O)NR2R3, -C(=W)NR2R3, -C(=W)NH(CH2)p-(aminoácido), un residuo de un aminoácido o -(CH2)p(aminoácido), donde si R5' es hidrógeno, F, Cl, Br, -NO2, -CN, -OR2, -NR2R2, -NHSO2-alquilo C1-3 ó -NHCO-alquilo C1-3, entonces al menos uno de R4', R6' y R7' no es hidrógeno; (c) Z es acilo opcionalmente sustituido o insustituido , -C(=O)NH2, -C(=W)NH2, -C(=O)NHR2, -C(=W)NHR2, -C(=O)NR2R3, -C(=W)NR2R3, -C(=W)NH(CH2)p-(aminoácido), un residuo de un aminoácido, -(CH2)p(aminoácido), -C(=O)R3, -C(=O)H, -C(=W)H, -C(=O)R2, -C(=W)R2, -C(=O)OR3, -C(=O)OH, -C(=W)OH, -C(=O)OR2, -C(=W)OR2, -C(=O)SH, -C(=W)SH, -C(=O)SR2, -C(=W)SR2, alquilo lineal o ramificado opcionalmente sustituido o insustituido, alquenilo o alquinilo (tal como un lineal o ramificado opcionalmente sustituido o insustituido alquilo C1-6, alquenilo C2-6 o alquinilo C2-6 y en particular CH3, CF3, bromuro de vinilo, -CR2R2-S(O)n-R3, -CR2R2NH2, -CR2R2NHR2, -CR2R2NR2R3 y -CR2R2-C(=O)R2), -CN o halo (F, Cl, Br ó I); (d) Y es O, S ó S(O)n; (e) cada W es independientemente O, S, -NH2, -NHR2, -NR2R2, -N-CN, -N-NH2, -N-NHR2, -N-NR2R3, -N-OH ó -N-OR2; (f) cada R2 es independientemente hidrógeno, o un alquilo inferior lineal o ramificado opcionalmente sustituido o insustituido, alquenilo o alquinilo (tal como un lineal o ramificado opcionalmente sustituido alquilo C1-3, alquenilo C2-4 o alquinilo C2-4, y en particular CH3, CF3, bromuro de vinilo, -CR2R2-S(O)n-R3, -CR2R2NH2, -CR2R2NHR2, -CR2R2NR2R3 y -CR2R2-C(=O)R2); (g) cada R3 es independientemente hidrógeno, alquilo lineal o ramificado opcionalmente sustituido o insustituido, alquenilo o alquinilo (tal como un lineal o ramificado opcionalmente sustituido o insustituido alquilo C1-6, alquenilo C2-6 o alquinilo C2-6 y en particular CH3, CF3, bromuro de vinilo, -CR2R2-S(O)n-R3, -CR2R2NH2, -CR2R2NHR2, -CR2R2NR2R3 y -CR2R2-C(=O)R2), arilo opcionalmente sustituido o insustituido (tal como fenilo), heterociclo opcionalmente sustituido o insustituido, opcionalmente sustituido o insustituido alquilarilo, opcionalmente sustituido o insustituido alquilheterociclo, opcionalmente sustituido o insustituido aralquilo, heterociclo opcionalmente sustituido o insustituido-alquilo; (h) cada n es independientemente 0, 1 ó 2; y (i) cada p es independientemente 0, 1, 2, 3, 4 ó 5; (j) donde si uno o más de los sustituyentes lineales o ramificados opcionalmente sustituidos alquilo, alquenilo, alquinilo, alquilo inferior, alquenilo inferior o alquinilo inferior, acilo, arilo, heterociclo, alcarilo, alc-heteroarilo, arilalquilo o alquilheterociclo está sustituido, entonces preferentemente está sustituido con uno o más entre halógenos (F, Cl, Br ó I), -OH, -OR2, -SH, -SR2, oxima, hidrazina, -C(=O)H, -C(=W)H, -C(=O)R2, -C(=W)R2, -C(=O)OH, -C(=W)OH, -C(=O)OR2, -C(=W)OR2, -C(=O)SH, -C(=W)SH, -C(=O)SR2, -C(=W)SR2, -C(=O)NH2, -C(=W)NH2, -C(=O)NHR2, -C(=W)NHR2, -C(=O)NR2R3, -C(=W)NR2R3, -NH2, -NHR2, -NR2R3, -NHSO2-alquilo C1-3, -NR2SO2-alquilo C1-3, -NHCO-alquilo C1-3, -NR2CO-alquilo C1-3, -S(O)n-R3, alcoxi C1-3, tioéter C1-3, un residuo de un aminoácido tal como -NH(CH2)p-(aminoácido) ó -C(=W)NH(CH2)p-(aminoácido). Los compuestos poseen actividad antiviral (es decir anti VIH) o bien se metabolizan en un compuesto que presenta tal actividad. Composiciones farmacéuticas que los contienen y sus usos en la fabricación de medicamentos.
ARP020101341A 2001-04-11 2002-04-11 Fenilindoles; sus composiciones farmaceuticas y sus usos AR035857A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28339301P 2001-04-11 2001-04-11

Publications (1)

Publication Number Publication Date
AR035857A1 true AR035857A1 (es) 2004-07-21

Family

ID=23085844

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101341A AR035857A1 (es) 2001-04-11 2002-04-11 Fenilindoles; sus composiciones farmaceuticas y sus usos

Country Status (10)

Country Link
US (3) US6710068B2 (es)
EP (1) EP1390029B1 (es)
AR (1) AR035857A1 (es)
AT (1) ATE451921T1 (es)
AU (1) AU2002254616B2 (es)
BR (1) BR0208790A (es)
CA (1) CA2444501C (es)
DE (1) DE60234760D1 (es)
TW (1) TWI294875B (es)
WO (1) WO2002083126A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1305313B1 (it) * 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
AR035857A1 (es) * 2001-04-11 2004-07-21 Novirio Pharmaceuticals Ltd Fenilindoles; sus composiciones farmaceuticas y sus usos
JP2006500355A (ja) * 2002-08-07 2006-01-05 イデニクス（ケイマン）リミテツド Ｈｉｖ治療用の置換フェニルインドール類
WO2004041837A1 (en) * 2002-10-31 2004-05-21 Metabasis Therapeutics, Inc. Novel cytarabine monophosphate prodrugs
EP1620407A2 (en) * 2003-04-28 2006-02-01 Idenix (Cayman) Limited Oxo-pyrimidine compounds
US7439268B2 (en) * 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
WO2006054182A2 (en) 2004-09-16 2006-05-26 Idenix Pharmaceuticals, Inc. Phosphoindoles as hiv inhibitors
WO2006041961A1 (en) * 2004-10-05 2006-04-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
PT1809602E (pt) 2004-10-27 2008-12-15 Janssen Pharmaceutica Nv Derivados de indole úteis como moduladores do receptor da progesterona
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
RU2008127501A (ru) * 2006-01-13 2010-02-20 Вайет (Us) Сульфонилзамещенные 1н-индолы в качастве лигандов 5-гидрокситриптаминовых рецепторов
CA2664396A1 (en) 2006-09-29 2008-04-10 Idenix Pharmaceuticals, Inc. Enantiomerically pure phosphoindoles as hiv inhibitors
JP2010505834A (ja) * 2006-10-06 2010-02-25 メルク エンド カムパニー インコーポレーテッド 非ヌクレオシド系逆転写酵素阻害剤
US7550625B2 (en) * 2007-10-19 2009-06-23 Idexx Laboratories Esters of florfenicol
US20100292232A1 (en) * 2007-11-09 2010-11-18 Daniel Elleder Non-nucleoside reverse transcriptase inhibitors
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
MX2010009203A (es) * 2008-02-22 2010-11-10 Irm Llc Compuestos y composiciones como modulares de la actividad de gpr119.
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
ES2646834T3 (es) 2010-08-20 2017-12-18 Amira Pharmaceuticals, Inc. Inhibidores de autotaxina y usos de los mismos
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
WO2015042052A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
JP2016530209A (ja) 2013-09-17 2016-09-29 ファーマケア，インク． ビニルオートタキシン阻害剤化合物
JP2016531874A (ja) 2013-09-26 2016-10-13 ファーマケア，インク． オートタキシン阻害剤化合物
MY182095A (en) 2013-11-22 2021-01-18 Sabre Therapeutics Llc Autotaxin inhibitor compounds
CA2937548C (en) 2014-02-13 2022-10-25 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
ES2915267T3 (es) 2015-05-27 2022-06-21 Sabre Therapeutics Llc Inhibidores de autotaxina y usos de los mismos
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3304019A1 (de) * 1983-02-07 1984-08-09 Kali-Chemie Pharma Gmbh, 3000 Hannover 3-acyloxy-1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4866084A (en) 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
GB8823693D0 (en) * 1988-10-08 1988-11-16 Hartopp R Injector cleaning apparatus
US5527819A (en) 1991-09-06 1996-06-18 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
US5124327A (en) 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
WO1993005020A1 (en) * 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
DE4217964A1 (de) 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
US5633457A (en) * 1992-06-05 1997-05-27 Triangle Special Products Fuel injection cleaning and testing system and apparatus
JPH08507067A (ja) * 1993-02-24 1996-07-30 メルク エンド カンパニー インコーポレーテッド Ｈｉｖ逆転写酵素阻害剤
US5489685A (en) 1994-05-12 1996-02-06 Merck & Co., Ltd. Method of synthesizing furo[2,3-b]pyridine carboxylic acid esters
EP0711768B1 (en) 1994-05-31 2002-02-13 Mitsui Chemicals, Inc. Benzimidazole derivative
US5734081A (en) 1994-08-05 1998-03-31 Warner-Lambert Company Arylthio compounds
US5981525A (en) 1995-01-10 1999-11-09 Smithkline Beecham Corporation Indole derivatives useful in the treatment of osteoporosis
GB9614347D0 (en) 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
US5830894A (en) 1997-02-21 1998-11-03 Viropharma Incorporated Methods for preventing and treating pestivirus infection and associated diseases
US5935982A (en) 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US20020091148A1 (en) * 2000-09-15 2002-07-11 Bamaung Nwe Y. 3-substituted indole antiproliferative angiogenesis inhibitors
AR035857A1 (es) * 2001-04-11 2004-07-21 Novirio Pharmaceuticals Ltd Fenilindoles; sus composiciones farmaceuticas y sus usos
JP2006500355A (ja) * 2002-08-07 2006-01-05 イデニクス（ケイマン）リミテツド Ｈｉｖ治療用の置換フェニルインドール類
US7406822B2 (en) * 2005-06-30 2008-08-05 Caterpillar Inc. Particulate trap regeneration system and control strategy
US7481048B2 (en) * 2005-06-30 2009-01-27 Caterpillar Inc. Regeneration assembly

Also Published As

Publication number Publication date
CA2444501A1 (en) 2002-10-24
EP1390029A1 (en) 2004-02-25
EP1390029B1 (en) 2009-12-16
TW200422291A (en) 2004-11-01
US20020193415A1 (en) 2002-12-19
WO2002083126A1 (en) 2002-10-24
EP1390029A4 (en) 2005-11-30
BR0208790A (pt) 2004-03-30
TWI294875B (en) 2008-03-21
ATE451921T1 (de) 2010-01-15
AU2002254616B2 (en) 2007-09-06
DE60234760D1 (de) 2010-01-28
CA2444501C (en) 2009-11-17
US20040180888A1 (en) 2004-09-16
US20070293668A1 (en) 2007-12-20
US6710068B2 (en) 2004-03-23

Similar Documents

Publication Publication Date Title
AR035857A1 (es) Fenilindoles; sus composiciones farmaceuticas y sus usos
CA2475432A1 (en) 2,4,6-triamino-1,3,5-triazine derivative
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
PA8607001A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
CA2457054A1 (en) Activator of peroxisome proliferator-activated receptor .delta.
NI201000022A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
HUP0300138A2 (en) Cyclic amine derivatives as ccr5 antagonists, their production and use and pharmaceutical compositions containing them
AR074773A1 (es) Piridazinonas sustituidas con fenilo en la posicion 4, su utilizacion como herbicidas e insecticidas en composiciones y metodos que los incluyen e intermediarios para su sintesis.
FI952423A0 (fi) Aniliinit mineraaliöljyjen merkkiaineina
CO5631432A2 (es) Derivados de n-[fenil(piepidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica
ATE273290T1 (de) Optische aufheller
ECSP034524A (es) Derivados de pirina con actividad inhibidora de quinasa ikb (ikk-beta)
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
ES2248498T3 (es) Derivados amidas, sulfonamidas o carbamatos aromaticos de acrilonitrilo y composiciones cosmeticas fotoprotectoras que los contienen.
HUP0100638A2 (hu) FP agonistákként alkalmazható aromás C16-C20-szubsztituált tetrahidroprosztaglandinok és ezeket tartalmazó gyógyszerkészítmények
ES2158726T3 (es) Utilizacion en tincion capilar de condensados de quinolina-5,8-dionas o de quinoxalina-5,8-dionas y de pirroles, anilinas o indoles sustituidos.
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR036634A1 (es) Composicion de tenido que contiene un compuesto de para-aminofenol o para-fenilen diamina sustituido por un radical silanico
HUP0102099A2 (hu) Szubsztituált 2-oxo-alkánsav-[2-(indol-3-il)-etil]-amid-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
AR039689A1 (es) Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso
CO5540387A2 (es) Nuevos derivados de oxazolidinonas como antibacterianos
ECSP045338A (es) Nuevos derivados de indolizina 1,2,3 substituida, inhibidores de los fgfs, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2006000045A (es) Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica
CO4950515A1 (es) Nuevos derivados de la quinolina para uso medicinal
HRP20090474T1 (hr) Postupak i intermedijeri za sintezu kaspofungina

Legal Events

Date Code Title Description
FB Suspension of granting procedure